Spots Global Cancer Trial Database for small lymphocytic lymphoma (sll)
Every month we try and update this database with for small lymphocytic lymphoma (sll) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | NCT03263637 | Relapsed or Ref... Acute Myeloid L... Acute Lymphocyt... Chronic Lymphoc... High Risk Myelo... Chronic Myelomo... Richter's Syndr... B-cell Non-Hodg... T-cell Non-Hodg... Small Lymphocyt... Multiple Myelom... | AZD4573 | 18 Years - 130 Years | AstraZeneca | |
| Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | NCT05144347 | Non-Hodgkin's L... Activated B-Cel... Mantle Cell Lym... Chronic Lymphoc... Small Lymphocyt... | XL114 | 18 Years - | Exelixis | |
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | NCT01306643 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | NCT05753501 | Hematologic Can... | ABBV-101 | 18 Years - | AbbVie | |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05105841 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Ibrutinib Obinutuzumab | 20 Years - | AbbVie | |
| Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas | NCT01282424 | Follicular Lymp... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies | NCT03588598 | Chronic Lymphoc... Small Lymphocyt... B-Cell Non-Hodg... | SHC014748M | 18 Years - 75 Years | Nanjing Sanhome Pharmaceutical, Co., Ltd. | |
| Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax | NCT04419519 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax mono... Venetoclax with... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota | |
| Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | NCT01647971 | Non-Hodgkins Ly... B-cell Lymphoma Waldenstrom's M... Marginal Zone L... Chronic Lymphoc... Small Lymphocyt... Primary Central... | Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy | NCT03406156 | Chronic Lymphoc... Small Lymphocyt... | Obinutuzumab Bendamustine Venetoclax | 18 Years - 99 Years | AbbVie | |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | NCT05753501 | Hematologic Can... | ABBV-101 | 18 Years - | AbbVie | |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | NCT05131022 | Chronic Lymphoc... Small Lymphocyt... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Waldenstrom Mac... Primary Central... | NX-5948 | 18 Years - | Nurix Therapeutics, Inc. | |
| A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML | NCT03547115 | Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... Chronic Lymphoc... Diffuse Large B... Acute Myeloid L... | voruciclib mono... voruciclib and ... | 18 Years - | MEI Pharma, Inc. | |
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | NCT05720052 | Relapsed or Ref... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Chronic Lymphoc... Small Lymphocyt... Marginal Zone L... | MS-553 | 18 Years - | MingSight Pharmaceuticals, Inc | |
| Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) | NCT01754870 | Chronic Lymphoc... Small Lymphocyt... | Bendamustine an... | 18 Years - | University of Wisconsin, Madison | |
| Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | NCT05168930 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Zanubrutinib | 18 Years - | Dana-Farber Cancer Institute | |
| Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) | NCT00923507 | Waldenstrom Mac... Lymphoplasmacyt... Monoclonal B-Ce... Small Lymphocyt... CLL (Chronic Ly... | 18 Years - 110 Years | National Institutes of Health Clinical Center (CC) | ||
| Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | NCT05168930 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Zanubrutinib | 18 Years - | Dana-Farber Cancer Institute | |
| A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies | NCT00861510 | Lymphoma, Mantl... Leukemia, Lymph... Leukemia, Hairy... Waldenstrom Mac... Multiple Myelom... | ON01910 Na | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota | |
| Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00694590 | Chronic Lymphoc... Small Lymphocyt... | plerixafor | 18 Years - 80 Years | Sanofi | |
| First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma | NCT03625037 | DLBCL High-grade B-ce... Primary Mediast... FL MCL Small Lymphocyt... Marginal Zone L... | Epcoritamab | 18 Years - | Genmab | |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05105841 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Ibrutinib Obinutuzumab | 20 Years - | AbbVie | |
| Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | NCT01497496 | Chronic Lymphoc... Small Lymphocyt... | High Dose Methy... Ofatumumab Lenalidomide | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | NCT01306643 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | NCT02362035 | Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk... | Acalabrutinib Pembrolizumab | 18 Years - | Acerta Pharma BV | |
| Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00694590 | Chronic Lymphoc... Small Lymphocyt... | plerixafor | 18 Years - 80 Years | Sanofi | |
| A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT02966756 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax | 18 Years - | AbbVie | |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | NCT02362035 | Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk... | Acalabrutinib Pembrolizumab | 18 Years - | Acerta Pharma BV | |
| A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | NCT01203930 | Chronic Lymphoc... Small Lymphocyt... | Idelalisib Rituximab | 65 Years - | Gilead Sciences | |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | NCT04830137 | Chronic Lymphoc... Small Lymphocyt... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... Follicular Lymp... Diffuse Large B... Primary Central... | NX-2127 | 18 Years - | Nurix Therapeutics, Inc. | |
| Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | NCT01497496 | Chronic Lymphoc... Small Lymphocyt... | High Dose Methy... Ofatumumab Lenalidomide | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
